Haverford Financial Services Inc. cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 12,547 shares of the medical research company's stock after selling 1,047 shares during the period. Thermo Fisher Scientific makes up about 2.0% of Haverford Financial Services Inc.'s investment portfolio, making the stock its 24th largest holding. Haverford Financial Services Inc.'s holdings in Thermo Fisher Scientific were worth $6,527,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $26,000. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $28,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Missouri Trust & Investment Co bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.23% of the company's stock.
Thermo Fisher Scientific Price Performance
Shares of NYSE:TMO traded down $1.98 during mid-day trading on Thursday, reaching $511.69. The stock had a trading volume of 1,249,700 shares, compared to its average volume of 1,534,660. The company has a market cap of $193.04 billion, a P/E ratio of 30.96, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The business's 50 day moving average price is $542.80 and its 200 day moving average price is $553.64. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.34%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.
Insider Buying and Selling
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,900 shares of company stock worth $13,106,062. Corporate insiders own 0.34% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. UBS Group raised their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Sanford C. Bernstein raised Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price on the stock in a report on Friday, January 10th. Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Finally, Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $653.23.
View Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
